Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

31.29
Delayed Data
As of Apr 01
 +0.67 / +2.19%
Today’s Change
30.13
Today|||52-Week Range
52.58
-38.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$572.0M

Company Description

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. It is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus. These inhibitors include members of the direct acting antiviral inhibitor classes - protease, NS5A and nucleotide polymerase - as well as a host-targeted antiviral inhibitor class targeted against cyclophilin. Additionally, the company has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community methicillin-resistant Staphylococcus aureus infections. Enanta Pharmaceuticals was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Contact Information

Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown Massachusetts 02472
P:(617) 607-0800
Investor Relations:
(617) 607-0710

Employees

Shareholders

Mutual fund holders36.47%
Individual stakeholders35.36%
Other institutional22.63%

Top Executives

Jay R. LulyPresident, Chief Executive Officer & Director
Paul J. MellettChief Financial Officer & Senior VP-Administration
Yat-Sun OrChief Scientific Officer & SVP-Research
Nathaniel S. GardinerSecretary, Senior Vice President & General Counsel
Timothy D. OcainSenior VP-New Product Strategy & Development

To view my watchlist

Not a member yet?

Sign up now for a free account